These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26124443)

  • 1. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
    Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
    Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Roles of AXIN1 and AXIN2 in Tankyrase Inhibitor-Induced Formation of Degradasomes and β-Catenin Degradation.
    Thorvaldsen TE; Pedersen NM; Wenzel EM; Stenmark H
    PLoS One; 2017; 12(1):e0170508. PubMed ID: 28107521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.
    Pedersen NM; Thorvaldsen TE; Schultz SW; Wenzel EM; Stenmark H
    PLoS One; 2016; 11(8):e0160507. PubMed ID: 27482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
    Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
    J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
    Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Tankyrase to Fight WNT-dependent Tumours.
    Thorvaldsen TE
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):81-88. PubMed ID: 28371398
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for tankyrases as antineoplastic targets in lung cancer.
    Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
    BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
    Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
    Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
    Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
    Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-Specific Regulation of the Wnt/β-Catenin Pathway by PAGE4 Inhibition of Tankyrase.
    Koirala S; Klein J; Zheng Y; Glenn NO; Eisemann T; Fon Tacer K; Miller DJ; Kulak O; Lu M; Finkelstein DB; Neale G; Tillman H; Vogel P; Strand DW; Lum L; Brautigam CA; Pascal JM; Clements WK; Potts PR
    Cell Rep; 2020 Jul; 32(3):107922. PubMed ID: 32698014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.
    Cheng H; Li X; Wang C; Chen Y; Li S; Tan J; Tan B; He Y
    Cancer Lett; 2019 Feb; 443():80-90. PubMed ID: 30472184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
    Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
    Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
    Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
    Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
    Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.